BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
3/26/2020 3:19:09 AM | Browse: 1140 | Download: 2623
 |
Received |
|
2019-11-22 13:38 |
|
Peer-Review Started |
|
2019-11-22 13:47 |
|
First Decision by Editorial Office Director |
|
2019-12-12 00:21 |
|
Return for Revision |
|
2019-12-12 00:21 |
|
Revised |
|
2020-02-19 13:09 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2020-02-27 07:33 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2020-02-28 06:43 |
|
Articles in Press |
|
2020-02-28 06:43 |
|
Edit the Manuscript by Language Editor |
|
2020-03-04 21:58 |
|
Typeset the Manuscript |
|
2020-03-13 08:36 |
|
Publish the Manuscript Online |
|
2020-03-26 03:19 |
| ISSN |
2307-8960 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Pharmacology & Pharmacy |
| Manuscript Type |
Retrospective Study |
| Article Title |
Ruxolitinib add-on in corticosteroid-refractory graft-vs-host disease after allogeneic stem cell transplantation: Results from a retrospective study on 38 Chinese patients
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Si-Hua Dang, Qin Liu, Rong Xie, Na Shen, Shu Zhou, Wei Shi, Wen Liu, Ping Zou, Yong You and Zhao-Dong Zhong |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Zhao-Dong Zhong, MD, Doctor, Doctor, Department of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 13 Hangkong Road, Hankou District, Wuhan 430030, Hubei Province, China. whxhzzd008@126.com |
| Key Words |
Graft-vs-host disease; Graft-vs-leukemia effect; Allogeneic hematopoietic stem cell transplantation; Ruxolitinib; Treatment; Antifungal drugs |
| Core Tip |
This study aimed to investigate the effect and safety of ruxolitinib add-on in the treatment of patients with steroid-refractory (SR) acute (a) and chronic (c) graft-vs-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation. An important finding of this retrospective case series was that the use of ruxolitinib as a salvage therapy for SR-GVHD resulted in an overall response rate of 100% in patients with SR-aGVHD (complete response: 80%) and 82.1% in patients with SR-cGVHD (complete response: 10.7%). In addition, this was achieved with a lower dose (5-10 mg/d) of ruxolitinib than previous reports, indicating that the dose of ruxolitinib could be lowered when used in combination with antifungal drugs (CYP2C9/CYP3A4 inhibitors). |
| Publish Date |
2020-03-26 03:19 |
| Citation |
Dang SH, Liu Q, Xie R, Shen N, Zhou S, Shi W, Liu W, Zou P, You Y, Zhong ZD. Ruxolitinib add-on in corticosteroid-refractory graft-vs-host disease after allogeneic stem cell transplantation: Results from a retrospective study on 38 Chinese patients. World J Clin Cases 2020; 8(6): 1065-1073 |
| URL |
https://www.wjgnet.com/2307-8960/full/v8/i6/1065.htm |
| DOI |
https://dx.doi.org/10.12998/wjcc.v8.i6.1065 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
